A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With RIMM

P

Peking University

Status

Enrolling

Conditions

Multiple Myeloma
Renal Injury

Treatments

Drug: Bortezomib

Study type

Interventional

Funder types

Other

Identifiers

NCT06203145
BCD-KPD-AutoHSCT of RIMM

Details and patient eligibility

About

Multiple myeloma (MM) is still an incurable hematological tumor, and renal involvement is the main factor of poor prognosis. The recovery of renal function can partially reverse its poor outcome. Although the 5-year survival rate of MM patients has significantly improved after entering the era of new drugs, patients with severe renal insufficiency still have a high early mortality.The purpose of this study is to investigate whether early intensive chemotherapy can reverse the proportion of renal insufficiency, is to investigate the treatment effect of RIMM patients with different renal pathological types, and is also to investigate whether autoHSCT can further partially save renal function in RIMM patients.

Full description

For patients with multiple myeloma with renal impairment, the same disease stage and the same treatment regimen have different therapeutic effects. In the era of new drugs, studies have shown that early reduction of the free light chain in serum is the key to reversing renal function. The International Myeloma Working Group recommends the following drugs for the treatment of RIMM patients: 1. regimens based on proteasome inhibitors; 2. regimens based on immunomodulators. Here, we explore a clinical study on the Whole-course Management (BCD-KPD-AutoHSCT) scheme for patients with RIMM.

Enrollment

30 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Adults aged 18 years or older
  2. Confirmed diagnosis of symptomatic myeloma with renal impairment
  3. Confirmed myeloma-associated nephropathy (e.g. light chain cast nephropathy, AL amyloidosis, MIDD etc.) on renal biopsy
  4. Willingness and eligibility for autologous hematopoietic stem cell transplantation

Exclusion criteria

  1. Pre-existing chronic kidney disease unrelated to myeloma, such as diabetic nephropathy or hypertensive nephropathy
  2. Plasma cell leukemia or extramedullary plasmacytoma
  3. Contraindications or prior severe allergic reactions to study medications
  4. Co-existing malignancy
  5. Co-existing medical conditions unsuitable for enrollment as determined by researchers, such as recent cardiovascular event, active infection etc.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

30 participants in 1 patient group

BCD-KPD-AutoHSCT
Experimental group
Description:
BCD-KPD-AutoHSCT/BCD-AutoHSCT
Treatment:
Drug: Bortezomib

Trial contacts and locations

1

Loading...

Central trial contact

Bo Tang, PhD.; Yujun Dong, M.D.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems